Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Circulating Endothelial Progenitor Cells and Aortic Aneurysm (ANOPEC3)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified August 2013 by Hopital Jean Minjoz
Sponsor:
Information provided by (Responsible Party):
Prof. Sidney Chocron, Hopital Jean Minjoz
ClinicalTrials.gov Identifier:
NCT01918982
First received: August 6, 2013
Last updated: August 7, 2013
Last verified: August 2013
  Purpose

We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.


Condition
- Aortic Aneurysm

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Interest of Circulating Endothelial Progenitor Cells CD34+144+CD14- and CD34+VEGF-R2+CD14- in the Follow-up of Aortic Aneurysm

Resource links provided by NLM:


Further study details as provided by Hopital Jean Minjoz:

Primary Outcome Measures:
  • Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood concentration [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Patients are followed for 2 years


Estimated Enrollment: 40
Study Start Date: October 2013
Estimated Study Completion Date: May 2016
Estimated Primary Completion Date: February 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts
Aortic aneurysm
Patients with aortic aneurysm >30mm and < 50mm

Detailed Description:

Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- have been shown to be inversely correlated to aortic aneurysm size. We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level. 40 patients followed for known aortic aneurysm >30mm and <50mm will be followed up every 6 months during 2 years. Each 6 months they will have a consultation by their physiologist with an echo or a CT-scan. At the same time, a 10ML blood sample will be taken to assess the circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with aortic aneurysm

Criteria

Inclusion Criteria:

  • Aortic aneurysm size >30mm and > 50mm

Exclusion Criteria:

  • Infectious disease
  • Inflammatory disease
  • Liver insuffisency
  • Cancer evolutive
  • Pregnant women
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01918982

Contacts
Contact: Sidney Chocron +33381533121 sidney.chocron@univ-fcomte.fr

Sponsors and Collaborators
Hopital Jean Minjoz
Investigators
Principal Investigator: Sidney Chocron, MD, PhD Université de Franche-comté. France
Principal Investigator: Andrea Perrotti, MD Université de Franche-Comté. France
Principal Investigator: Simon Rinckenbach, MD, PhD Université de Franche-Comté. France
Principal Investigator: Siamak Davani, MD, PhD Université de Franche-Comté. France
  More Information

Publications:
Responsible Party: Prof. Sidney Chocron, MD, PhD, Hopital Jean Minjoz
ClinicalTrials.gov Identifier: NCT01918982     History of Changes
Other Study ID Numbers: 147/362
Study First Received: August 6, 2013
Last Updated: August 7, 2013
Health Authority: France: Health Agency

Keywords provided by Hopital Jean Minjoz:
Aortic aneurysm
circulating endothelial progenitor cells

Additional relevant MeSH terms:
Aneurysm
Aortic Aneurysm
Aortic Diseases
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on November 24, 2014